AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2022
Mar 3, 2022
31868_dirs_2022-03-03_6a6e34b4-57c1-446e-beaa-ca4f141ab608.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2022-03-01
Reporting Person: Jones Michael L (Exec. Director, Finance - PAO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-01 | Common Stock | M | 2300 | $4.73 | Acquired | 13498 | Direct |
| 2022-03-01 | Common Stock | S | 2300 | $17.20 | Disposed | 11198 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-01 | Emp. Stock Option (Right to Buy) | $4.73 | M | 2300 | Disposed | 2022-03-01 | Common Stock (2300) | Direct |
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20